DE60305903D1 - Tropanderivative als ccr5-modulatoren - Google Patents

Tropanderivative als ccr5-modulatoren

Info

Publication number
DE60305903D1
DE60305903D1 DE60305903T DE60305903T DE60305903D1 DE 60305903 D1 DE60305903 D1 DE 60305903D1 DE 60305903 T DE60305903 T DE 60305903T DE 60305903 T DE60305903 T DE 60305903T DE 60305903 D1 DE60305903 D1 DE 60305903D1
Authority
DE
Germany
Prior art keywords
tropanderivative
ccr5 modulators
ccr5
modulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60305903T
Other languages
English (en)
Other versions
DE60305903T2 (de
Inventor
Patricia Ann Basford
Peter Thomas Stephenson
Stefan Colin John Taylor
Anthony Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0208071.1A external-priority patent/GB0208071D0/en
Priority claimed from GB0301575A external-priority patent/GB0301575D0/en
Application filed by Pfizer Inc filed Critical Pfizer Inc
Application granted granted Critical
Publication of DE60305903D1 publication Critical patent/DE60305903D1/de
Publication of DE60305903T2 publication Critical patent/DE60305903T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
DE60305903T 2002-04-08 2003-03-31 Tropanderivative als ccr5-modulatoren Expired - Lifetime DE60305903T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0208071 2002-04-08
GBGB0208071.1A GB0208071D0 (en) 2002-04-08 2002-04-08 Tropane derivatives useful in therapy
GB0301575 2003-01-23
GB0301575A GB0301575D0 (en) 2003-01-23 2003-01-23 Tropane derivatives useful in therapy
PCT/IB2003/001220 WO2003084954A1 (en) 2002-04-08 2003-03-31 Tropane derivatives as ccr5 modulators

Publications (2)

Publication Number Publication Date
DE60305903D1 true DE60305903D1 (de) 2006-07-20
DE60305903T2 DE60305903T2 (de) 2007-03-08

Family

ID=28793308

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60305903T Expired - Lifetime DE60305903T2 (de) 2002-04-08 2003-03-31 Tropanderivative als ccr5-modulatoren

Country Status (41)

Country Link
EP (1) EP1492789B1 (de)
JP (2) JP3793200B2 (de)
KR (1) KR100734685B1 (de)
CN (1) CN1324025C (de)
AP (1) AP1789A (de)
AR (1) AR039383A1 (de)
AT (1) ATE328882T1 (de)
AU (1) AU2003214503B2 (de)
BR (1) BR0309118A (de)
CA (1) CA2481482C (de)
CR (1) CR7514A (de)
CU (1) CU23282A3 (de)
CY (1) CY1106114T1 (de)
DE (1) DE60305903T2 (de)
DK (1) DK1492789T3 (de)
DO (1) DOP2003000624A (de)
EA (1) EA007590B1 (de)
ES (1) ES2263960T3 (de)
GE (1) GEP20074210B (de)
HK (1) HK1076102A1 (de)
HN (1) HN2003000114A (de)
HR (1) HRP20040940A2 (de)
IL (1) IL164261A0 (de)
IS (1) IS2577B (de)
MA (1) MA27190A1 (de)
MX (1) MXPA04009220A (de)
MY (1) MY134223A (de)
NI (1) NI200300053A (de)
NO (1) NO329674B1 (de)
NZ (1) NZ535452A (de)
OA (1) OA12798A (de)
PA (1) PA8570801A1 (de)
PE (1) PE20040082A1 (de)
PL (1) PL372968A1 (de)
PT (1) PT1492789E (de)
RS (1) RS51550B (de)
SI (1) SI1492789T1 (de)
TN (1) TNSN04194A1 (de)
TW (1) TWI280130B (de)
UY (1) UY27752A1 (de)
WO (1) WO2003084954A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1492789T3 (da) * 2002-04-08 2006-09-11 Pfizer Tropanderivater som CCR5-modulatorer
US6855724B2 (en) 2002-04-08 2005-02-15 Agouron Pharmaceuticals, Inc. Tropane derivatives useful in therapy
CA2579609A1 (en) 2003-09-10 2005-03-17 Virochem Pharma Inc. Spirohydantoin compounds and methods for the modulation of chemokine receptor activity
WO2005033107A1 (en) * 2003-10-03 2005-04-14 Pfizer Limited Imidazopyridine substituted tropane derivatives with ccr5 receptor antagonist activity for the treatment of hiv and inflammation
TW200533348A (en) 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
US8131026B2 (en) 2004-04-16 2012-03-06 Validity Sensors, Inc. Method and apparatus for fingerprint image reconstruction
US7751601B2 (en) 2004-10-04 2010-07-06 Validity Sensors, Inc. Fingerprint sensing assemblies and methods of making
WO2006064340A2 (en) * 2004-12-13 2006-06-22 Pfizer Limited Process for the preparation of n-acyl beta-aminoaldehydes
US7932235B2 (en) 2006-11-17 2011-04-26 Concert Pharmaceuticals, Inc. Triazolyl tropane derivatives
DK2134712T3 (da) 2007-04-13 2013-11-18 Dong Wha Pharm Co Ltd Aspartat af 1-cyclopropyl-6-fluoro-7-(8-methoxyimino-2,6-diaza-spiro(3, 4)oct-6-yl)-4-oxo-1,4-dihydro-(1,8) naphthyridin-3-karboxylsyre, fremgangsmåde til fremstilling af samme og antimikrobielt farmaceutisk sammensætning omfattende samme
US7947710B2 (en) 2007-08-27 2011-05-24 Theravance, Inc. Disubstituted alkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
CN101712679B (zh) 2008-10-08 2013-04-10 中国科学院上海药物研究所 一种酰胺类化合物、其药物组合物及其制备方法和用途
TW201129362A (en) * 2009-11-21 2011-09-01 Hoffmann La Roche Heterocyclic antiviral compounds
EA201200855A1 (ru) 2009-12-23 2013-04-30 Айронвуд Фармасьютикелз, Инк. Модуляторы crth2
KR20130025899A (ko) 2010-04-02 2013-03-12 피비코-1 엘엘씨 Ｃｃｒ５ 길항제，ｈｉｖ―1 프로테아제 억제제 및 약동학적 인핸서를 포함하는 병용 요법
US20130259830A1 (en) 2010-07-12 2013-10-03 Ironwood Pharmaceuticals, Inc. Crth2 modulators
US20130216552A1 (en) 2010-07-12 2013-08-22 Ironwood Pharmaceuticals, Inc. Crth2 modulators
HUE047354T2 (hu) 2011-05-18 2020-04-28 Vertex Pharmaceuticals Europe Ltd Ivacaftor deuterizált származékai
US20140271680A1 (en) 2011-08-12 2014-09-18 Universite Paris-Est Creteil Val De Marne Methods and pharmaceutical compositions for treatment of pulmonary hypertension
CN103159754A (zh) * 2011-12-19 2013-06-19 中国科学院上海药物研究所 一种氨基丙基取代托烷胺类化合物、其药物组合物及其制备方法和用途
JP6146990B2 (ja) * 2012-11-16 2017-06-14 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化されたｃｆｔｒ増強物質
GB201321749D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321748D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
CA2981495C (en) 2015-03-31 2023-09-26 Vertex Pharmaceuticals (Europe) Limited Deuterated vx-661
US10759721B2 (en) 2015-09-25 2020-09-01 Vertex Pharmaceuticals (Europe) Limited Deuterated CFTR potentiators
JP2017105824A (ja) * 2017-02-10 2017-06-15 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化されたｃｆｔｒ増強物質
KR20200096560A (ko) 2017-12-01 2020-08-12 버텍스 파마슈티칼스 인코포레이티드 낭포성 섬유증 막관통 조절 인자의 제조 방법
EP3768256A4 (de) 2018-03-19 2021-11-24 Emory University Pan-tropische eingangsinhibitoren
JP6654223B2 (ja) * 2018-08-13 2020-02-26 バーテックス ファーマシューティカルズ （ヨーロッパ） リミテッド 重水素化されたｃｆｔｒ増強物質
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20001420A1 (es) * 1998-12-23 2000-12-18 Pfizer Moduladores de ccr5
WO2001080106A1 (fr) * 2000-04-19 2001-10-25 Satoshi Yamazaki Procede de diffusion d'outil publicitaire et support magnetique pour le logiciel
PT1284974E (pt) * 2000-05-26 2004-06-30 Pfizer Derivados de triazoliltropano como moduladores de ccr5
DK1492789T3 (da) * 2002-04-08 2006-09-11 Pfizer Tropanderivater som CCR5-modulatorer

Also Published As

Publication number Publication date
NO20044615L (no) 2004-10-26
CR7514A (es) 2004-11-08
DK1492789T3 (da) 2006-09-11
CN1646526A (zh) 2005-07-27
RS88804A (en) 2006-12-15
DOP2003000624A (es) 2003-10-15
AR039383A1 (es) 2005-02-16
NZ535452A (en) 2006-11-30
BR0309118A (pt) 2005-02-01
GEP20074210B (en) 2007-10-10
JP2005532285A (ja) 2005-10-27
NI200300053A (es) 2005-11-01
HN2003000114A (es) 2004-05-05
CN1324025C (zh) 2007-07-04
MY134223A (en) 2007-11-30
UY27752A1 (es) 2003-11-28
EP1492789B1 (de) 2006-06-07
PT1492789E (pt) 2006-09-29
PE20040082A1 (es) 2004-03-20
JP2006182784A (ja) 2006-07-13
EP1492789A1 (de) 2005-01-05
CA2481482A1 (en) 2003-10-16
DE60305903T2 (de) 2007-03-08
NO329674B1 (no) 2010-11-29
AP2004003147A0 (en) 2004-09-30
AP1789A (en) 2007-10-05
IS2577B (is) 2010-02-15
SI1492789T1 (sl) 2006-10-31
EA007590B1 (ru) 2006-12-29
TNSN04194A1 (fr) 2007-03-12
WO2003084954A1 (en) 2003-10-16
IS7453A (is) 2004-09-16
IL164261A0 (en) 2005-12-18
OA12798A (en) 2006-07-10
RS51550B (en) 2011-06-30
MXPA04009220A (es) 2005-09-30
CA2481482C (en) 2009-11-10
HRP20040940A2 (en) 2005-04-30
CY1106114T1 (el) 2011-06-08
JP3793200B2 (ja) 2006-07-05
KR100734685B1 (ko) 2007-07-02
AU2003214503A1 (en) 2003-10-20
AU2003214503B2 (en) 2008-08-07
PL372968A1 (en) 2005-08-08
JP4571078B2 (ja) 2010-10-27
KR20040099420A (ko) 2004-11-26
MA27190A1 (fr) 2005-01-03
HK1076102A1 (en) 2006-01-06
TW200403242A (en) 2004-03-01
ES2263960T3 (es) 2006-12-16
ATE328882T1 (de) 2006-06-15
TWI280130B (en) 2007-05-01
EA200401167A1 (ru) 2005-04-28
PA8570801A1 (es) 2004-11-26
CU23282A3 (es) 2008-06-30

Similar Documents

Publication Publication Date Title
DE60305903D1 (de) Tropanderivative als ccr5-modulatoren
DE50304983D1 (de) Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren
DE60330694D1 (de) Pyrimidopyrimidone als kinaseinhibitoren
ATE407134T1 (de) Triazolyltropanderivate als ccr5-modulatoren
ATE341543T1 (de) Pyridinoylpiperidine als 5-ht1f agonisten
DE60309263D1 (de) Anzeigesystem
DE602004015724D1 (de) Diazepinoindolderivate als kinaseinhibitoren
ATE525377T1 (de) Imidazoä1,5-aüpyrazine als inhibitoren von tyrosinkinase
DE602004024420D1 (de) Chinazolinderivate als antitumormittel
ATE456558T1 (de) Gabanerge modulatoren
DK1550629T3 (da) Elevatorsystem
DK2447252T3 (da) Theramuteinmodulatorer
FI20021310A (fi) Jauhin
DE602004004295D1 (de) 6-ä(substituiertes)phenylütriazolopyrimidine als antikrebsmittel
ATE394372T1 (de) G-lactamderivate als prostaglandinagonisten
ATE418542T1 (de) Als ccr5-antagonisten verwendbare aryloxim- piperazine
DE502004003823D1 (de) Kran
DK1581307T3 (da) Irs modulatorer
DE60336338D1 (de) Sulfonylaminopyrazole als pestizide
FI20031706A (fi) Hissijärjestelmä
FI20031722A0 (fi) Hissijärjestelmä
DE602004006424D1 (de) Piperidinderivate als ccr5-rezeptormodulatoren
FI5622U1 (fi) Nostin
FI5809U1 (fi) Verhouslevy
FI20031710A0 (fi) Hissijärjestelmä

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: DERZEIT KEIN VERTRETER BESTELLT